Markhot Ferenc Oktatokorhaz Es Rendelointezet

At Markhot Ferenc Oktatokorhaz Es Rendelointezet, researchers are exploring new strategies to lower the risk of stroke in patients who have experienced an acute ischemic event or a high‑risk transient ischemic attack. The study evaluates whether the oral agent milvexian can safely reduce recurrent ischemic episodes compared with standard care.

• Stroke recurrence prevention
• Antithrombotic efficacy assessment
• Safety profiling in acute stroke patients

The site’s multidisciplinary team of 24 investigators contributes to eight ongoing trials, with cardiovascular research representing a key focus of its clinical portfolio.

The ophthalmology department is conducting a trial to determine if citicoline eye drops can preserve visual fields in individuals with progressing open‑angle glaucoma, alongside routine clinical management. The goal is to improve visual outcomes and reduce disease progression.

• Visual field preservation
• Topical neuroprotection
• Glaucoma progression monitoring

With a dedicated group of ophthalmologists, the hospital leverages its expertise to address common eye conditions while participating in the broader network of eight clinical studies.

Investigators are testing whether adding XEMBIFY to standard therapy can lower the frequency of serious bacterial infections in patients with B‑cell chronic lymphocytic leukemia, multiple myeloma, or non‑Hodgkin lymphoma who have hypogammaglobulinemia. The trial aims to enhance infection control in these vulnerable populations.

• Infection reduction in hematologic malignancies
• Immunoglobulin deficiency management
• Combination therapy safety evaluation

The hospital’s hematology unit collaborates closely with oncology specialists to bring innovative treatments to patients with blood‑related cancers.

A separate study compares luspatercept with epoetin alfa in low‑risk myelodysplastic syndrome patients to see which agent better promotes red blood cell production and reduces transfusion dependence. This research seeks to improve quality of life for individuals with this bone‑marrow disorder.

• Anemia management in MDS
• Erythropoiesis‑stimulating agents comparison
• Transfusion reduction strategies

Through its eight active trials, the center integrates cancer research across hematologic and solid‑tumor domains, supported by a robust team of 24 investigators.